

Certificate of Analysis

Cell Count	2.0 Million per vial
Viability	90%
CD4+	99.28%
CD4+ CD25+	96.23%
CD25+ CD127-	95.72%
% Suppression at 1:8 Treg:Effector Ratio	78%
Sterility Testing	Negative for bacteria and fungi

Donor Information




Donor ID	154
Gender	Male
Age	42
Race	Caucasian
Height	6'7"
Weight	336
ABO Type	O positive

HLA Typing

	Allele 1	Allele 2
HLA-A	02:01	31:01
HLA-B	15:01	35:02
HLA-C	03:04	04:01
HLA-DRB1	01:01	11:04


Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1 and are negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

5120MY21



Co-Culture of Tregs Resulted in Suppression of Anti- CD3-mediated CD8+ T Cell Proliferation of Allogeneic Peripheral Blood Mononuclear Cells (PBMCs).

In short, in a 96 well plate, 250,000 CFSE-labelled allogeneic responder PBMC were plated/well in the presence of 0.2 µg/mL anti-CD3 and varying number of Tregs at responder to Treg ratio shown in the chart above. The plate was incubated in a 37 deg C, 6% CO₂ incubator. After 5 days of culture, individual wells were harvested and labelled with PE-labelled anti-CD8 mAb. Data was acquired on a flow cytometer and the extent of proliferation (Division Index, DI) was analyzed using FCS Express 4.0. % Suppression = 100- (DI in the presence of Treg/DI in lthe absence of Treg) x 100.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.